Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava”) securities between June 22, 2021 and August 24, 2021.
Cassava investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.
After the market closed on August 24, 2021, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) alleging that the foundational science and studies supporting Cassava’s use of its proprietary drug Simufilam are based on systemic data manipulation and misrepresentation. The Citizen Petition requests that the FDA halt two ongoing trials of Simufilam.
Following this news, Cassava’s stock price fell over 30% on August 25, 2021, closing at $80.86 per share on August 25, 2021, down 31.4% from its previous close of $117.83 per share on August 24, 2021.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.